Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335936 | 0.80 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL6334571 | 0.74 | P2RX7 (0.46) | MEN1KMT2A | |
| SCHEMBL6404299 | 0.73 | BRAF (0.37) | MEN1KMT2A | |
| SCHEMBL6408514 | 0.73 | KDM4E (0.36) | MEN1KMT2A | |
| SCHEMBL6489320 | 0.70 | HPGD (0.46) | HSD17B10MEN1KMT2A | |
| SCHEMBL6334422 | 0.70 | HPGD (0.46) | HSD17B10MEN1KMT2A | |
| SCHEMBL6343579 | 0.64 | SMN1; SMN2 (0.40) | HSD17B10MEN1KMT2A | |
| SCHEMBL6336265 | 0.64 | PI4KB (0.43) | MEN1KMT2API4KB | |
| SCHEMBL6334489 | 0.64 | ADORA1 (0.38) | PIK3CDPIK3R1 | |
| SCHEMBL6334486 | 0.64 | ADORA1 (0.38) | PIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969713-B2 | Piperidine and piperazine acetamide derivatives | ASTRAZENECA AB (SE) | 2005-11-29 | — | — | US | disclosed |
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013721-A1 | Novel piperidine and piperazine derivatives | IL5, VIP, EP300 | PIK3CD 376/4885PIK3R1 1159/4885HSD17B10 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.